**CRITERIA FULLFILLMENT OF PRIMARY Sjögren’s SYNDROME ACCORDING TO TIME OF EVOLUTION OF SICCA SYMPTOMS**


1. Universidad Autónoma de Nuevo León, Reumatología e Inmunología Clínica, Monterrey, México

**Background:** Primary Sjögren’s Syndrome (PSS) is an autoimmune disease characterized by sicca symptoms, autoimmune features and lymphocytic infiltrate in exocrine glands. Classification and diagnosis of PSS is performed by applying 2002 AECG, 2012 ACR or 2016 EULAR criteria. Time of evolution of symptoms has been associated with different clinical, serological and pathology findings.

**Objectives:** Document sicca profiles and compare findings according to time of evolution of symptoms.

**Methods:** A descriptive retrospective observational study was performed in 116 patients with sicca symptoms in a Rheumatology center in México. Patients were separated according to time of evolution of sicca symptoms in ≤1 year, ≤2 years, ≤3 years, and ≥3 years. Clinical, serological, and histopathology features were assessed at each established time.

Time from symptom onset to diagnosis was reported in median and interquartile range (IQR); age at symptom onset and age at diagnosis was expressed in mean and standard deviation (SD).

Patients were classified as PSS if they fulfilled the 2002 AECG or 2016 ACR-EULAR criteria. Serology of Rheumatoid factor (RF), ANA, Anti-Ro, and Anti-La were documented.

**Results:** One hundred and sixteen sicca patients had a complete profile and 97 (83.62%) fulfilled AECG 2002 SSP criteria. Eighty-two (70.6%) patients with an ocular staining score were able to classify as PSS using the 2016 EULAR criteria.

Of the sicca cohort, 112 (96.6%) were female. The mean age of symptom onset was 48.4 (SD 13.11) years, and the mean age at diagnosis was 53.33 (SD 12.43) years. The median time from symptom onset to diagnosis was 36 (IQR 12-84) months.

**Conclusion:** Time of evolution of symptoms has a major impact on the profile of PSS. Longer symptom duration was associated with more severe clinical, serological and histopathological profiles.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.922

**AB0302**

**FACTORS ASSOCIATED WITH GESTATIONAL DIABETES MELLITUS (GDM) IN A MULTI-ETHNIC SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) COHORT**

S. S. Shahari1, R. Mustafar2, M. S. Mohamed Said1, R. Abd Rahman3.

1. Universiti Kebangsaan Malaysia Medical Centre, Rheumatology Unit, Department of Medicine, Cheras, Malaysia
2. Universiti Kebangsaan Malaysia Medical Centre, Nephrology Unit, Department of Medicine, Cheras, Malaysia
3. Universiti Kebangsaan Malaysia Medical Centre, Obstetrics and Gynaecology, Cheras, Malaysia

**Background:** The risks of insulin resistance and diabetes mellitus are elevated in systemic lupus erythematosus (SLE) patients. The use of glucocorticoid and anti-double stranded DNA antibodies positive are among the factors reported to be associated with the risk of gestational diabetes mellitus (GDM) in SLE patients. However, the relationship between GDM in Asian SLE patients is still obscure.

**Objectives:** To determine the prevalence of gestational diabetes mellitus (GDM) in a multi-ethnic SLE cohort in Malaysia and the associated risk factors.

**Methods:** This was a retrospective study of SLE pregnant women who have completed their antenatal care in Universiti Kebangsaan Malaysia Medical Centre (UKMMC) from 2004 until 2019. Screening and diagnosis of gestational diabetes mellitus (GDM) were as recommended in the guidelines by the Ministry of Health Malaysia. Information on SLE disease activity and treatment at 6 months before pregnancy and during pregnancy were determined from the medical records. Univariate and multi-variable logistic regression analyses were performed to determine the factors associated with GDM in the SLE patients.

**Results:** A total of 89 patients with 202 pregnancies were included in the study. Malay was the predominant ethnic in this cohort (n=82, 67.2%), followed by Chinese (n=33, 27.0%) and Indian (n=7, 5.7%). The most common system involvement of SLE was musculoskeletal, (n=91, 74.6%), followed by haematological (n=78, 63.9%), lupus nephritis (54.9%, n=67) and mucocutaneous (n=64, 54.1%). The prevalence of GDM was 8.9% (n=18). More patients with GDM had positive anti-cardiolipin IgG antibody (aCL IgG) and lupus anticoagulant (LA) antibody as compared to the patients with no GDM, (55.6% vs 25.8%, p=0.01) and (50.0% vs 25.4%, p=0.05) respectively. On the other hand, the use of hydroxychloroquine (HCQ) in pregnancy was significantly lower in GDM patients (11.1%) as compared to no GDM group (39.1%), p<0.02. There was no significant difference in the ethnicity, SLE system involvement, disease activity status and immunosuppressant use including steroid, azathioprine and cyclosporine A at 6 months before and during pregnancy between the GDM and non-GDM group. A forward logistic regression which include aCL IgG, LA and HCO use in pregnancy, only the HCO use remained significantly associated with lower risk of GDM in the model with OR=0.12, 95% CI=0.02-0.94, p=0.04.

**Conclusion:** Our study demonstrates the potential benefit of hydroxychloroquine in reducing the risk of gestational diabetes mellitus in SLE patients. The prevalence of antiphospholipid antibodies particularly aCL IgG and LA was found to be higher among patients with GDM. Further prospective studies are needed to confirm this association.

**REFERENCES:**